Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Jang, Miran ^a   Yew, Poh Yin ^a   Hasegawa, Kosei ^b   Ikeda, Yuji ^a   Fujiwara, Keiichi ^b   Fleming, Gini F ^a   Nakamura, Yusuke ^a,c   Park, Jae Hyun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c THE UNIVERSITY OF CHICAGO   (United States)

Author keywords

malignant ascites; next generation sequencing; ovarian cancer; T cell receptor; tumor immunity

Indexed keywords

ARTICLE; CELL EXPANSION; CELL POPULATION; CLINICAL ARTICLE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALIGNANT PLEURA EFFUSION; NEXT GENERATION SEQUENCING; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84941791242     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1030561     Document Type: Article

References (43)

1. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
2. A.Ayhan, M.Gultekin, C.Taskiran, P.Dursun, P.Firat, G.Bozdag, N.Y.Celik, K.Yuce. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 2007; 17:68-75; PMID:17291234; http://dx.doi.org/10.1111/j.1525-1438.2006.00777.x
3. S.L.Parsons, M.W.Lang, R.J.Steele. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996; 22:237-9; PMID:8654603; http://dx.doi.org/10.1016/S0748-7983(96)80009-6
4. B.Sheid. Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 1992; 62:153-8; PMID:1371714; http://dx.doi.org/10.1016/0304-3835(92)90186-Y
5. C.G.Ioannides, C.D.Platsoucas, S.Rashed, J.T.Wharton, C.L.Edwards, R.S.Freedman. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991; 51:4257-65; PMID:1868446
6. A.D.Santin, P.L.Hermonat, A.Ravaggi, S.Bellone, J.J.Roman, C.V.Smith, S.Pecorelli, A.Radominska-Pandya, M.J.Cannon, G.P.Parham. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 2001; 51:254-61; PMID:11408737; http://dx.doi.org/10.1159/000058060
7. R.L.Giuntoli, 2nd, T.J.Webb, A.Zoso, O.Rogers, T.P.Diaz-Montes, R.E.Bristow, M.Oelke. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009; 29:2875-84; PMID:19661290
8. T.F.Gajewski, H.Schreiber, Y.X.Fu. Innate and adaptive immune cells in the tumor microenvironment. Nature Immunol 2013; 14:1014-22; PMID: 24048123; http://dx.doi.org/10.1038/ni.2703
9. R.Yigit, C.G.Figdor, P.L.Zusterzeel, J.M.Pots, R.Torensma, L.F.Massuger. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 2011; 47:1883-9; PMID:21514148; http://dx.doi.org/10.1016/j.ejca.2011.03.026
10. A.Facciabene, G.T.Motz, G.Coukos. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72:2162-71; PMID:22549946; http://dx.doi.org/10.1158/0008-5472.CAN-11-3687
11. B.S.Nedergaard, M.Ladekarl, H.F.Thomsen, J.R.Nyengaard, K.Nielsen. Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer 2007; 97:1135-8; PMID:17940503; http://dx.doi.org/10.1038/sj.bjc.6604001
12. G.Erdag, J.T.Schaefer, M.E.Smolkin, D.H.Deacon, S.M.Shea, L.T.Dengel, J.W.Patterson, C.L.Slingluff, Jr. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72:1070-80; PMID:22266112; http://dx.doi.org/10.1158/0008-5472.CAN-11-3218
13. O.Nakano, M.Sato, Y.Naito, K.Suzuki, S.Orikasa, M.Aizawa, Y.Suzuki, I.Shintaku, H.Nagura, H.Ohtani. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-6; PMID:11431351
14. F.Pages, J.Galon, M.C.Dieu-Nosjean, E.Tartour, C.Sautes-Fridman, W.H.Fridman. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/onc.2009.416
15. M.E.Dudley, J.R.Wunderlich, P.F.Robbins, J.C.Yang, P.Hwu, D.J.Schwartzentruber, S.L.Topalian, R.Sherry, N.P.Restifo, A.M.Hubicki et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
16. H.Bosmuller, S.Haitchi-Petnehazy, G.Webersinke, R.Marschon, F.Roithmeier, W.Stummvoll, T.Fehm, M.Klier-Richter, I.Bonzheim, A.Staebler et al. Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch 2011; 459:183-91; PMID:21713364; http://dx.doi.org/10.1007/s00428-011-1110-1
17. T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram, M.Evdemon-Hogan, J.R.Conejo-Garcia, L.Zhang, M.Burow et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
18. D.Scaviner, M.P.Lefranc. The human T cell receptor alpha variable (TRAV) genes. Exp Clin Immunogenet 2000; 17:83-96; PMID:10810225; http://dx.doi.org/10.1159/000019128
19. G.Folch, M.P.Lefranc. The human T cell receptor beta variable (TRBV) genes. Exp Clin Immunogenet 2000; 17:42-54; PMID:10686482; http://dx.doi.org/10.1159/000019123
20. D.Scaviner, M.P.Lefranc. The human T cell receptor alpha joining (TRAJ) genes. Exp Clin Immunogenet 2000; 17:97-106; PMID:10810226; http://dx.doi.org/10.1159/000019129
21. G.Folch, M.P.Lefranc. The human T cell receptor beta diversity (TRBD) and beta joining (TRBJ) genes. Exp Clin Immunogenet 2000; 17:107-14; PMID:10810227; http://dx.doi.org/10.1159/000019130
22. P.D.Baum, V.Venturi, D.A.Price. Wrestling with the repertoire: the promise and perils of next generation sequencing for antigen receptors. Eur J Immunol 2012; 42:2834-9; PMID:23108932; http://dx.doi.org/10.1002/eji.201242999
23. Q.Qi, Y.Liu, Y.Cheng, J.Glanville, D.Zhang, J.Y.Lee, R.A.Olshen, C.M.Weyand, S.D.Boyd, J.J.Goronzy. Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci USA 2014; 111:13139-44; PMID:25157137; http://dx.doi.org/10.1073/pnas.1409155111
24. K.Naylor, G.Li, A.N.Vallejo, W.W.Lee, K.Koetz, E.Bryl, J.Witkowski, J.Fulbright, C.M.Weyand, J.J.Goronzy. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174:7446-52; PMID:15905594; http://dx.doi.org/10.4049/jimmunol.174.11.7446
25. P.D.Baum, J.J.Young, D.Schmidt, Q.Zhang, R.Hoh, M.Busch, J.Martin, S.Deeks, J.M.McCune. Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. Blood 2012; 119:3469-77; PMID:22371879; http://dx.doi.org/10.1182/blood-2011-11-395384
26. F.A.Sinicrope, R.L.Rego, S.M.Ansell, K.L.Knutson, N.R.Foster, D.J.Sargent. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137:1270-9; PMID:19577568; http://dx.doi.org/10.1053/j.gastro.2009.06.053
27. R.Kirk. Risk factors. CD8+:FOXP3+ cell ratio is a novel survival marker for colorectal cancer. Nat Rev Clin Oncol 2010; 7:299; PMID:20527684; http://dx.doi.org/10.1038/nrclinonc.2010.79
28. H.Imai, M.Saio, K.Nonaka, T.Suwa, N.Umemura, G.F.Ouyang, J.Nakagawa, H.Tomita, S.Osada, Y.Sugiyama et al. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer sci 2007; 98:416-23; PMID:17270031; http://dx.doi.org/10.1111/j.1349-7006.2006.00385.x
29. C.C.Preston, M.J.Maurer, A.L.Oberg, D.W.Visscher, K.R.Kalli, L.C.Hartmann, E.L.Goode, K.L.Knutson. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS one 2013; 8:e80063; PMID:24244610; http://dx.doi.org/10.1371/journal.pone.0080063
30. N.P.Restifo, M.E.Dudley, S.A.Rosenberg. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
31. L.Zhang, J.R.Conejo-Garcia, D.Katsaros, P.A.Gimotty, M.Massobrio, G.Regnani, A.Makrigiannakis, H.Gray, K.Schlienger, M.N.Liebman et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
32. A.Bonertz, J.Weitz, D.H.Pietsch, N.N.Rahbari, C.Schlude, Y.Ge, S.Juenger, I.Vlodavsky, K.Khazaie, D.Jaeger et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311-21; PMID:19809157; http://dx.doi.org/10.1172/JCI39608
33. N.C.Robson, S.Hoves, E.Maraskovsky, M.Schnurr. Presentation of tumour antigens by dendritic cells and challenges faced. Curr Opin Immunol 2010; 22:137-44; PMID:20116984; http://dx.doi.org/10.1016/j.coi.2010.01.002
34. P.F.Gallagher, B.Fazekas de St Groth, J.F.Miller. CD4 and CD8 molecules can physically associate with the same T-cell receptor. Proc Natl Acad Sci USA 1989; 86:10044-8; PMID:2513572; http://dx.doi.org/10.1073/pnas.86.24.10044
35. X.J.Qin, H.Z.Shi, J.M.Deng, Q.L.Liang, J.Jiang, Z.J.Ye. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009; 15:2231-7; PMID:19318474; http://dx.doi.org/10.1158/1078-0432.CCR-08-2641
36. F.Castellino, A.Y.Huang, G.Altan-Bonnet, S.Stoll, C.Scheinecker, R.N.Germain. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006; 440:890-5; PMID:16612374; http://dx.doi.org/10.1038/nature04651
37. A.Rot, U.H.von Andrian. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22:891-928; PMID:15032599; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104543
38. L.M.Ebert, P.Schaerli, B.Moser. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol 2005; 42:799-809; PMID:15829268; http://dx.doi.org/10.1016/j.molimm.2004.06.040
39. T.H.Schreiber, V.Shinder, D.W.Cain, R.Alon, R.Sackstein. Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. Blood 2007; 109:1381-6; PMID:17038526; http://dx.doi.org/10.1182/blood-2006-07-032995
40. H.S.Robins, P.V.Campregher, S.K.Srivastava, A.Wacher, C.J.Turtle, O.Kahsai, S.R.Riddell, E.H.Warren, C.S.Carlson. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009; 114:4099-107; PMID:19706884; http://dx.doi.org/10.1182/blood-2009-04-217604
41. V.Giudicelli, D.Chaume, M.P.Lefranc. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 2005; 33:D256-61; PMID:15608191; http://dx.doi.org/10.1093/nar/gki010
42. M.P.Lefranc, V.Giudicelli, Q.Kaas, E.Duprat, J.Jabado-Michaloud, D.Scaviner, C.Ginestoux, O.Clement, D.Chaume, G.Lefranc. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 2005; 33:D593-7; PMID:15608269; http://dx.doi.org/10.1093/nar/gki065
43. B.Langmead, S.L.Salzberg. Fast gapped-read alignment with Bowtie 2. Nature methods 2012; 9:357-9; PMID:22388286; http://dx.doi.org/10.1038/nmeth.1923